Skip NavigationSkip to Content

Covalent Small Molecule Immunomodulators Targeting the Protease Active Site

  1. Author:
    Kim,Hong-Rae
    Tagirasa,Ravichandra
    Yoo,Euna
  2. Author Address

    NCI, Chem Biol Lab, Frederick, MD 21702 USA.
    1. Year: 2021
    2. Date: May 13
    3. Epub Date: 2021 04 27
  1. Journal: Journal of medicinal chemistry
  2. AMER CHEMICAL SOC,
    1. 64
    2. 9
    3. Pages: 5291-5322
  3. Type of Article: Article
  4. ISSN: 0022-2623
  1. Abstract:

    Cells of the immune system utilize multiple proteases to regulate cell functions and orchestrate innate and adaptive immune responses. Dysregulated protease activities are implicated in many immune-related disorders; thus, protease inhibitors have been actively investigated for pharmaceutical development. Although historically considered challenging with concerns about toxicity, compounds that covalently modify the protease active site represent an important class of agents, emerging not only as chemical probes but also as approved drugs. Here, we provide an overview of technologies useful for the study of proteases with the focus on recent advances in chemoproteomic methods and screening platforms. By highlighting covalent inhibitors that have been designed to target immunomodulatory proteases, we identify opportunities for the development of small molecule immunomodulators.

    See More

External Sources

  1. DOI: 10.1021/acs.jmedchem.1c00172
  2. PMID: 33904753
  3. WOS: 000651785800006

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel